OBJECTIVE: Sperm washing (SW) with intrauterine insemination (IUI) has been advocated as a safe, efficacious way to achieve pregnancy and to reduce the risk of human immunodeficiency virus (HIV) transmission in HIV-serodiscordant couples in which the male partner is HIV-infected. [1] [2] [3] HIV is present as free virions in seminal plasma and as cellassociated virus in non-spermatic cells. 4 Using sperm concentrate prepped free of these cell types provides safety from sexual transmission. 3 In the United States, few centers provide fertility care for HIV-serodiscordant couples. SW with intracytoplasmic sperm injection of sperm into mature eggs harvested for in vitro fertilization has been used as a first-line assisted reproduction treatment, although this method is often cost prohibitive and requires dedicated in vitro fertilization laboratory equipment. 2 The US Department of Health and Human Services recommends preexposure prophylaxis (PrEP) antiretroviral therapy for sexually active couples to reduce infection transmission rates. 5 For HIV-serodiscordant couples in which the female partner is seronegative, we initiated an innovative therapy of SW-IUI combined with PrEP to further reduce the risk of HIV transmission.
STUDY DESIGN: Eleven HIV-serodiscordant couples were treated with SW-IUI at Columbia University Medical Center from January 1, 2014 to October 2016 (IRB-AAAQ7656). All couples reported safe-sex practices with condoms. The pretreatment assessment for couples who considered SW-IUI is outlined in the Table. Selected couples gave informed written consent and were eligible to undergo a maximum of 6 attempts of SW-IUI. Ovulatory women underwent natural cycles, and anovulatory women underwent ovulation induction with clomiphene citrate. Superovulation with the use of clomiphene citrate was performed at the physician's discretion for women 35 years old or women who had previously failed IUI cycles. SW used techniques of gradient centrifugation and sperm migration (swim-up). 3 Motile sperm were collected for IUI. 3 IUI was performed 12 hours after a luteinizing hormone surge or 36 hours after the administration of recombinant human choriogonadotropin alfa trigger (Ovidrel). Women were prescribed emtricitabine and tenofovir disoproxil fumarate (Truvada) as PrEP the day before, the day of, and the day after the IUI. Female HIV testing was performed at each cycle start, at completion of treatment if not pregnant, and every 3 months throughout resultant pregnancies. 
